Table 1 Demographic and baseline characteristics of study patients (n = 30)
From: Effect of enhanced external counterpulsation treatment on renal function in cardiac patients
Characteristics | Â |
|---|---|
Age (yr), mean (SD) | 69.1 (13.8) |
Male | 23 (76.7%) |
Body mass index (kg/m2) , mean (SD) | 26.1 (4.9) |
Clinical history | Â |
Coronary artery disease | 29 (96.7%) |
Hypertension | 27 (90.0%) |
Diabetes | 23 (76.7%) |
Stroke | 8 (26.7%) |
Angina pectoris | 23 (76.7%) |
Heart failure | 7 (23.3%) |
Peripheral artery disease | 4 (13.3%) |
Smoking status | 10 (33.3%) |
Past smoker | 7 (70.0%) |
Current smoker | 3 (30.0%) |
Previous procedures | Â |
Coronary angiography | 27 (90.0%) |
Percutaneous coronary intervention | 12 (40.0%) |
Coronary artery bypass grafting | 6 (20.0%) |
Medication | Â |
Statin | 28 (93.3%) |
Aspirin or Clopidogrel | 27 (90.0%) |
ACE inhibitor or ARB | 23 (76.7%) |
Beta-blocker | 19 (63.3%) |
Nitrate | 17 (56.7%) |
Calcium-channel blocker (Diltiazem or Verapamil) | 10 (33.3%) |
Laboratory findings, mean (SD) | Â |
Hemoglobin (g/dL) | 12.9 (1.8) |
Albumin (g/dL) | 4.2 (0.4) |
Cholesterol (mg/dL) | 146.0 (27.0) |
HDL cholesterol (mg/dL) | 49.5 (12.2) |
LDL cholesterol (mg/dL) | 77.8 (19.6) |
Triglyceride (mg/dL) | 103.3 (48.7) |
Glucose (mg/dL) | 118.3 (27.6) |
Hemoglobin A1C (%) | 7.5 (1.3) |
LVEF (%) | 55.0 (17.9) |